Ozempic, Wegovy, Mounjaro, Zepbound: which FDA indication belongs to which brand?

As of October 20, 2026, FDA indications belong to the exact brand and formulation—not to a shared ingredient nickname. Ozempic’s semaglutide products are labeled around type 2 diabetes and specified cardiovascular or kidney outcomes; Wegovy’s semaglutide products include chronic weight management and other formulation-specific uses. Mounjaro’s tirzepatide label concerns type 2 diabetes and a specified cardiovascular outcome; Zepbound’s tirzepatide label concerns adult weight management and obstructive sleep apnea in adults with obesity. Sharing semaglutide or tirzepatide does not transfer an approval across brands. ^{1 2 3 4 5}

This is a label-navigation guide, not an efficacy comparison or a recommendation to switch. The semaglutide-versus-tirzepatide article handles the ingredient comparison. Here, the job is to catch a different error: saying “the molecule is FDA-approved for X” when the exact product in the offer has a different label.

Read the four-brand map by indication and population

These are compressed label summaries. Full labeling defines limitations, warnings, contraindications, populations and administration. The drug class also deserves precision: semaglutide is a GLP-1 receptor agonist; tirzepatide acts at both GIP and GLP-1 receptors. Calling all four simply “GLP-1s” can obscure product identity. ^{4 5}

Formulation can change the answer within a brand

The current Wegovy label includes both injection and tablets. Its injection has the pediatric-obesity and noncirrhotic MASH indications listed above; the tablet’s stated indications are adult weight management and adult cardiovascular risk reduction in the specified population. The MASH indication is under accelerated approval based on improvement in MASH and fibrosis, with continued approval potentially contingent on a confirmatory clinical-benefit trial. ³ That is not the same as claiming a proven long-term liver outcome.

Ozempic likewise has an injection and, in 2026, oral tablets. The oral label includes adult type 2 diabetes and a cardiovascular indication for adults with type 2 diabetes at high risk; the injection also has a type-2-diabetes-with-CKD outcome indication. ^{1 2} A practice that describes Ozempic as “injection only” or assumes every Ozempic presentation carries the same kidney claim is using an outdated shortcut.

On-label eligibility is not a treatment decision

An indication tells you what FDA reviewed for a product and population. It does not establish that an individual is eligible, that one brand is safer or more effective for them, or that an insurer will cover it. Current labels include meaningful boxed warnings and other precautions, and clinical history may change the plan. Off-label prescribing of an FDA-approved drug is a distinct issue from a product having an approved indication; the prescriber should name the distinction clearly.

A compounded preparation is not FDA-approved just because it contains the same active ingredient name. Nor does a social-media before/after image establish a brand’s label, the product’s source or a patient’s outcome. If a telehealth or wellness offer substitutes between brands or formulations, ask for the exact prescription and dispensing pharmacy; the verification guide lays out the provider-and-pharmacy check.

Three claims that sound similar but are not

“Semaglutide is approved for chronic weight management” is a molecule-level shortcut. The accurate question is whether the prescribed Wegovy formulation and the person’s qualifying population match that label. Ozempic shares semaglutide but has diabetes-centered indications; an Ozempic prescription for an obesity-only goal would not inherit Wegovy’s weight-management approval. ^{1 2 3}

“Tirzepatide has a cardiovascular indication” likewise needs a brand and population. Mounjaro’s August 2026 label change concerns major cardiovascular events in adults with type 2 diabetes at high risk. That does not make Zepbound approved for the same cardiovascular endpoint, and Zepbound’s obstructive-sleep-apnea indication does not migrate to Mounjaro. ^{4 5}

Finally, “Wegovy treats MASH” is incomplete. The current injection label describes adults with noncirrhotic MASH and moderate-to-advanced F2–F3 fibrosis under accelerated approval; the tablet label does not list that use. ³ Each of these examples is a reason to request the dispensing record, not a reason to infer that another brand is ineffective or unsafe.

A six-field label check to take to the visit

Write down the brand, ingredient, route/formulation, labeled condition, qualifying population, and date the label was checked. Then ask which of those matches the proposed use, what benefit is being sought, what risks are being reviewed, and who will recheck the label when a new indication or formulation appears. Treomark’s medical weight-management service page can help identify South Florida providers to question; the current label and individualized consultation—not an interchangeable brand chart—remain the final sources for a prescription decision.